Caribou Biosciences, Inc. CRBU
We are a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats ("CRISPR") genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our genome-editing platform is based on our novel chRDNA (CRISPR hybrid RNA-DNA, or "chRDNA," pronounced "chardonnay") genome-editing technology, which enables more precise genome editing of allogeneic cell therapies.
Our allogeneic, or off-the-shelf, chimeric antigen receptor ("CAR") -T ("CAR-T") cell therapy product candidates are manufactured in advance with cells from healthy donors, with the goal of enabling broad patient access, rapid patient treatment, and increased manufacturing scale. Our allogeneic CAR-T cell therapy product candidates in clinical development are directed at CD19 and B cell maturation antigen ("BCMA"), established cell surface targets against which autologous CAR-T cell therapeutics have already demonstrated clinical proof of concept. We use our chRDNA technology to armor our cell therapy product candidates through genome-editing strategies, such as checkpoint disruption and immune cloaking, to enhance activity against hematologic malignancies.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- United States
- Rest of world
| Region | FY2025 | FY2024 |
|---|---|---|
| United States | $9.5M | $9.3M |
| Rest of world | $1.7M | $724.0K |
As the company reported it, from the “Revenue - Schedule of Disaggregation of Revenue (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.2M | $10.0M | $34.5M | $13.9M | $9.6M | $12.4M | $5.8M | — |
| R&D | $109.4M | $130.2M | $112.1M | $82.2M | $52.3M | $34.4M | $23.6M | — |
| SG&A | $37.9M | $46.5M | $38.5M | $38.0M | $24.3M | $14.1M | $16.5M | — |
| Total operating expenses | $159.5M | $176.6M | $150.5M | $120.2M | $76.6M | $48.5M | $40.1M | — |
| Operating income | -$148.3M | -$166.6M | -$116.1M | -$106.4M | -$67.0M | -$36.1M | -$34.3M | — |
| Interest expense | — | — | — | — | $8.0K | $20.0K | $4.0K | — |
| Pre-tax income | -$148.7M | -$149.1M | -$101.9M | -$99.4M | -$66.6M | -$36.1M | -$31.0M | — |
| Income tax | $550.0K | $9.0K | $193.0K | $70.0K | $321.0K | $1.8M | $7.5M | — |
| Net income | -$148.1M | -$149.1M | -$102.1M | -$99.4M | -$66.9M | -$34.3M | -$23.4M | — |
| EPS, basic | -1.59 | -1.65 | -1.38 | -1.64 | -2.11 | — | — | — |
| EPS, diluted | -1.59 | -1.65 | -1.38 | -1.64 | -2.11 | -4.01 | -2.80 | — |
| Shares, diluted (wtd. avg.) | 93.4M | 90.3M | 73.8M | 60.8M | 31.7M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $12.4M | $16.3M | $51.2M | $58.4M | $240.5M | $16.0M | $41.1M | — |
| Short-term investments | $127.0M | $193.2M | $277.7M | $189.3M | $135.4M | $0 | — | — |
| Receivables | $69.0K | $265.0K | $148.0K | $202.0K | $1.2M | $150.0K | — | — |
| Total current assets | $145.2M | $219.4M | $338.8M | $260.2M | $391.2M | $24.3M | — | — |
| Property, plant and equipment | $6.8M | $19.3M | $18.3M | $10.7M | $4.9M | $3.5M | — | — |
| Total assets | $175.4M | $313.3M | $432.2M | $373.8M | $442.4M | $36.0M | — | — |
| Accounts payable | $5.8M | $2.5M | $3.1M | $1.1M | $4.0M | $2.6M | — | — |
| Total current liabilities | $25.4M | $30.7M | $28.3M | $28.1M | $25.8M | $12.4M | — | — |
| Total liabilities | $53.2M | $60.4M | $63.8M | $72.9M | $54.5M | $18.2M | — | — |
| Retained earnings | -$596.5M | -$448.4M | -$299.3M | -$197.2M | -$97.8M | -$30.9M | — | — |
| Total equity | $122.2M | $253.0M | $368.4M | $300.9M | $387.8M | -$23.4M | $7.5M | $29.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$111.0M | -$138.2M | -$93.3M | -$91.0M | -$32.5M | -$33.2M | -$32.0M | — |
| Depreciation and amortisation | $3.6M | $3.9M | $3.5M | $1.6M | $984.0K | $900.0K | $751.0K | — |
| Stock-based compensation | $12.7M | $16.7M | $13.8M | $11.7M | $3.4M | $1.0M | $1.2M | — |
| Capital expenditure | $1.4M | $4.9M | $11.6M | $6.5M | $2.1M | $317.0K | $884.0K | — |
| Investing cash flow | $102.2M | $86.6M | -$68.2M | -$93.2M | -$176.4M | $6.4M | $27.2M | — |
| Financing cash flow | $4.8M | $16.7M | $154.3M | $2.1M | $433.4M | $1.7M | $172.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001619856-26-000008.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $5.8M | $12.4M | $9.6M | $13.9M | $34.5M | $10.0M | $11.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$23.4M | -$34.3M | -$66.9M | -$99.4M | -$102.1M | -$149.1M | -$148.1M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |